122536-75-8

Basic information

• Product Name: (R)-1-CBZ-3-(BOC-AMINO) PYRROLIDINE
• Synonyms: 3-TERT-BUTOXYCARBONYLAMINO-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER, (R);(R)-1-CBZ-3-(BOC-AMINO) PYRROLIDINE;3-TERT-BUTOXYCARBONYLAMINO-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER;(R)-3-tert-Butoxycarbonylaminopyrrolidine-1-carboxylic acid benzyl ester;(R)-1-Cbz-3-BocaMinopyrrolidin;benzyl (3R)-3-{[(tert-butoxy)carbonyl]aMino}pyrrolidine-1-carboxylate;(R)-benzyl 3-(tert-butoxycarbonyl)pyrrolidine-1-carboxylate
• CAS NO: 122536-75-8
• Molecular Formula: C₁₇H₂₄N₂O₄
• Molecular Weight: 320.38346
• Mol File: 122536-75-8.mol

Chemical Properties

• Boiling Point: 458.496 °C at 760 mmHg
• Flash Point: 231.091 °C
• Appearance: /
• Density: 1.174 g/cm³
• Vapor Pressure: 1.37E-08mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-1-CBZ-3-(BOC-AMINO) PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-CBZ-3-(BOC-AMINO) PYRROLIDINE(122536-75-8)
• EPA Substance Registry System: (R)-1-CBZ-3-(BOC-AMINO) PYRROLIDINE(122536-75-8)

Safety Data

• Hazardous Substances Data: 122536-75-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-CBZ-3-(BOC-AMINO) PYRROLIDINE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be selectively deprotected and activated, facilitating the creation of complex organic molecules with potential therapeutic effects.
Used in Organic Synthesis:
(R)-1-CBZ-3-(BOC-AMINO) PYRROLIDINE is used as a building block for the preparation of bioactive molecules due to its versatility in chemical transformations, allowing for the efficient synthesis of a wide range of organic compounds.
Used in Research and Development:
In the field of chemical research and development, (R)-1-CBZ-3-(BOC-AMINO) PYRROLIDINE serves as a valuable reagent for exploring novel chemical reactions and pathways, enhancing the understanding of organic chemistry and its applications in medicine and other industries.

InChI:InChI=1/C17H24N2O4/c1-17(2,3)23-15(20)18-14-9-10-19(11-14)16(21)22-12-13-7-5-4-6-8-13/h4-8,14H,9-12H2,1-3H3,(H,18,20)/t14-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 122536-73-6 benzyl (R)-3-amino-pyrrolidine-1-carboxylate 
• 501-53-1 benzyl chloroformate 
• 122536-71-4 (R)-3-azido-1-pyrrolidinecarboxylic acid phenylmethyl ester 
• 122536-69-0 (S)-3-<(methylsulfonyl)oxy>-1-pyrrolidinecarboxylic acid phenylmethyl ester 
• 122536-77-0 3-N-tert-butoxycarbonyl-3-(R)-aminopyrrolidine 
• 122536-76-9 3(S)-(tert-butoxycarbonylamino)pyrrolidine 
• 100858-32-0 (S)-3-hydroxy-1-pyrrolidinecarboxylic acid phenylmethyl ester 

Downstream Products

• 122536-77-0 3-N-tert-butoxycarbonyl-3-(R)-aminopyrrolidine 
• 870621-17-3 (R)-Cbz-3-aminopyrrolidine hydrochloride 
• 638217-49-9 benzyl (3R)-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine-1-carboxylate 

Relevant articles and documents

4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS

The present invention relates to substituted heterocyclic compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors/antagonists useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

Pyrimidine derivatives

A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R1, R2, R3, R4, R5, and R8 are as defined above.

PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS

The present invention provides compounds of (I) wherein R1, Y1, X1, Z1, X2, Y2, A, Y3, n, R and R2 are as defined in the specification, processes for their preparation

Antithrombotic agents

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well a

Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3- amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity

A series of amino acid prodrugs of racemic and chiral 7-(3-amino-1- pyrrolidinyl)-6-fluoro-1,8-naphthyridine-3-carboxylic acids, 1-cyclopropyl- 6,8-difluoro-3-quinolinecarboxylic acids, 1-cyclopropyl-6-fluoro-3- quinolinecarboxylic acids, and 5-amino-1-cyclopropyl-6,8-difluoro-3- quinolinecarboxylic acids have been prepared and evaluated for comparative antibacterial activity. Compounds were prepared by acylation of the 3-amino group of the pyrrolidine with common amino acids using standard peptide chemistry. This series has been compared with the parent compounds for antibacterial activity in vitro and in vivo as well as for comparative solubility. The amino acid analogues were less active in vitro, but had equal or increased efficacy in vivo. Indeed, it was proven that these compounds, which were stable to acid and base under the reaction conditions for their preparation, were rapidly cleaved in serum to give the parent quinolones. The amino acid derivatives showed a 3-70 times improved solubility when compared to the parent compounds. The most active compound of the series was [S- (R*,R*)]-7-[3-[(2-amino-1-oxopropyl)-amino]-1-pyrrolidinyl]-1-cyclopropyl- 6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid (PD 131112).